NDC-11 (Package) | NDC-9 (Product) | Generic Name (Descending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00781-9165-75 | 00781-9165 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | Oct. 21, 1988 | Nov. 17, 2014 | No Longer Used | |||
55390-0160-10 | 55390-0160 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | April 4, 2005 | Feb. 28, 2013 | No Longer Used | |||
55390-0161-10 | 55390-0161 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | April 4, 2005 | April 30, 2013 | No Longer Used | |||
55390-0162-10 | 55390-0162 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | April 4, 2005 | March 31, 2015 | No Longer Used | |||
55390-0163-01 | 55390-0163 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | April 8, 2005 | Dec. 31, 2014 | No Longer Used | |||
55390-0164-01 | 55390-0164 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | April 8, 2005 | Dec. 31, 2014 | No Longer Used | |||
55390-0375-10 | 55390-0375 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | March 9, 2009 | April 30, 2013 | No Longer Used | |||
55390-0376-10 | 55390-0376 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | March 9, 2009 | Jan. 31, 2013 | No Longer Used | |||
55390-0377-01 | 55390-0377 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | March 9, 2009 | April 30, 2013 | No Longer Used | |||
55648-0632-01 | 55648-0632 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
55648-0633-01 | 55648-0633 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
55648-0633-02 | 55648-0633 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
55648-0634-01 | 55648-0634 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
55648-0635-01 | 55648-0635 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
55648-0635-02 | 55648-0635 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
55648-0636-01 | 55648-0636 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
55648-0636-02 | 55648-0636 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
62756-0348-44 | 62756-0348 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 14, 2007 | Jan. 31, 2017 | No Longer Used | |
62756-0349-44 | 62756-0349 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 14, 2007 | Nov. 30, 2016 | No Longer Used | |
62756-0350-40 | 62756-0350 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 14, 2007 | Jan. 31, 2017 | No Longer Used | |
62756-0351-44 | 62756-0351 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 14, 2007 | Nov. 30, 2016 | No Longer Used | |
62756-0352-40 | 62756-0352 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 14, 2007 | Jan. 31, 2017 | No Longer Used | |
64679-0632-01 | 64679-0632 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
64679-0633-01 | 64679-0633 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
64679-0633-02 | 64679-0633 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
64679-0634-01 | 64679-0634 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
64679-0635-01 | 64679-0635 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
64679-0635-02 | 64679-0635 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
64679-0636-01 | 64679-0636 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
64679-0636-02 | 64679-0636 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
50242-0070-01 | 50242-0070 | Obinutuzumab | Gazyva | 1000.0 mg/40mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov. 1, 2013 | In Use | |
50242-0070-86 | 50242-0070 | Obinutuzumab | Gazyva | 1000.0 mg/40mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov. 4, 2013 | In Use | |
16729-0332-03 | 16729-0332 | OXALIPLATIN | OXALIPLATIN | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 17, 2018 | In Use | |
16729-0332-05 | 16729-0332 | OXALIPLATIN | OXALIPLATIN | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 17, 2018 | In Use | |
63323-0373-02 | 63323-0373 | ONDANSETRON HYDROCHLORIDE | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 18, 2009 | In Use | |
63323-0374-20 | 63323-0374 | ONDANSETRON HYDROCHLORIDE | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 18, 2009 | In Use | |
76045-0103-20 | 76045-0103 | ONDANSETRON HYDROCHLORIDE | Ondansetron | 4.0 mg/2mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 10, 2015 | In Use | |
35356-0679-10 | 35356-0679 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON HYDROCHLORIDE | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 25, 2007 | June 30, 2019 | In Use |
35356-0679-30 | 35356-0679 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON HYDROCHLORIDE | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 25, 2007 | June 30, 2019 | In Use |
51655-0800-04 | 51655-0800 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON HYDROCHLORIDE | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 30, 2014 | In Use | |
65293-0373-02 | 65293-0373 | ONDANSETRON HYDROCHLORIDE | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 18, 2009 | Jan. 31, 2015 | In Use |
65293-0373-25 | 65293-0373 | ONDANSETRON HYDROCHLORIDE | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 18, 2009 | Jan. 31, 2015 | In Use |
76045-0216-20 | 76045-0216 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON | 4.0 mg/2mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | May 31, 2022 | In Use | |
67457-0769-02 | 67457-0769 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON HYDROCHLORIDE | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 31, 2017 | In Use | |
51662-1539-01 | 51662-1539 | ONDANSETRON | ONDANSETRON | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 6, 2021 | In Use | |
00404-9930-02 | 00404-9930 | ONDANSETRON | ONDANSETRON | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jan. 13, 2022 | In Use | |
51662-1246-04 | 51662-1246 | ONDANSETRON | ONDANSETRON | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 19, 2018 | In Use | |
51662-1245-01 | 51662-1245 | ONDANSETRON | ONDANSETRON | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 23, 2018 | In Use | |
51662-1245-03 | 51662-1245 | ONDANSETRON | ONDANSETRON | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 23, 2018 | In Use | |
70518-3802-00 | 70518-3802 | ONDANSETRON | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | July 24, 2023 | In Use |
Found 10,000 results in 9 milliseconds — Export these results